afamitresgene autoleucel
Term · Oncology and biomedicine · MLC-T-ONC-000302
A treatment used for adults with synovial sarcoma that has the MAGE-A4 antigen and has spread to other parts of the body or cannot be removed by surgery. It is used in patients who have certain HLA-A*02 antigens and have received chemotherapy. It is also being studied in the treatment of other types of cancer. Afamitresgene autoleucel is made using a patient’s T cells (a type of immune system cell). A special T-cell receptor that can recognize the MAGE-A4 antigen is added to the T cells in the laboratory. These changed T cells are then grown in large numbers in the laboratory and given back to the patient by infusion. Afamitresgene autoleucel binds to the MAGE-A4 antigen, which is found on some types of cancer cells. This helps the body’s immune system kill cancer cells. Afamitresgene autoleucel is a type of cellular immunotherapy. Also called Tecelra.
A preparation of autologous human T lymphocytes transduced with a lentiviral vector encoding an affinity-enhanced T-cell receptor (TCR) specific for the human leukocyte antigen (HLA)-A2-restricted peptide human melanoma antigen A4 (MAGE-A4) C1032, with potential immunostimulatory and antineoplastic activities. Upon leukapheresis, isolation, transduction, expansion ex vivo, and reintroduction into the patient, afamitresgene autoleucel targets and binds to tumor cells expressing MAGE-A4. This results in cell death of MAGE-A4-expressing tumor cells. The tumor-associated antigen (TAA) MAGE-A4, a member of the MAGE-A family of cancer testis antigens, is overexpressed by a variety of cancer cell types.
| Identifier | MLC-T-ONC-000302 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | Tecelra; autologous genetically-modified MAGE-A4 C1032 T lymphocytes; afami-cel; autologous genetically-modified MAGE-A4 C1032 T cells; MAGE-A4C1032T; SPEAR T-cell ADP-A2M4; MAGE-A4 SPEAR T cells |
| References | NCI Dictionary of Cancer Terms; National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-000302",
"term": "afamitresgene autoleucel",
"field": "Oncology and biomedicine",
"definitions": [
"A treatment used for adults with synovial sarcoma that has the MAGE-A4 antigen and has spread to other parts of the body or cannot be removed by surgery. It is used in patients who have certain HLA-A*02 antigens and have received chemotherapy. It is also being studied in the treatment of other types of cancer. Afamitresgene autoleucel is made using a patient’s T cells (a type of immune system cell). A special T-cell receptor that can recognize the MAGE-A4 antigen is added to the T cells in the laboratory. These changed T cells are then grown in large numbers in the laboratory and given back to the patient by infusion. Afamitresgene autoleucel binds to the MAGE-A4 antigen, which is found on some types of cancer cells. This helps the body’s immune system kill cancer cells. Afamitresgene autoleucel is a type of cellular immunotherapy. Also called Tecelra.",
"A preparation of autologous human T lymphocytes transduced with a lentiviral vector encoding an affinity-enhanced T-cell receptor (TCR) specific for the human leukocyte antigen (HLA)-A2-restricted peptide human melanoma antigen A4 (MAGE-A4) C1032, with potential immunostimulatory and antineoplastic activities. Upon leukapheresis, isolation, transduction, expansion ex vivo, and reintroduction into the patient, afamitresgene autoleucel targets and binds to tumor cells expressing MAGE-A4. This results in cell death of MAGE-A4-expressing tumor cells. The tumor-associated antigen (TAA) MAGE-A4, a member of the MAGE-A family of cancer testis antigens, is overexpressed by a variety of cancer cell types."
],
"synonyms": [
"Tecelra",
"autologous genetically-modified MAGE-A4 C1032 T lymphocytes",
"afami-cel",
"autologous genetically-modified MAGE-A4 C1032 T cells",
"MAGE-A4C1032T",
"SPEAR T-cell ADP-A2M4",
"MAGE-A4 SPEAR T cells"
],
"references": [
"NCI Dictionary of Cancer Terms",
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/afamitresgene-autoleucel/"
}
Record 515 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.